Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program.
about
Daptomycin-nonsusceptible vancomycin-intermediate staphylococcus aureus vertebral osteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim-sulfamethoxazoleDaptomycin: an evidence-based review of its role in the treatment of Gram-positive infectionsCurrent concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococciIn vitro activity of daptomycin against Enterococcus faecalis under various conditions of growth-phases, inoculum and pHNH125 kills methicillin-resistant Staphylococcus aureus persisters by lipid bilayer disruption.Safety profiles of old and new antimicrobials for the treatment of MRSA infections.Penetration of daptomycin into bone and synovial fluid in joint replacement.Vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations: study protocol for a phase IIB randomized controlled trial.A potential role for daptomycin in enterococcal infections: what is the evidence?High-dose daptomycin and fosfomycin treatment of a patient with endocarditis caused by daptomycin-nonsusceptible Staphylococcus aureus: case reportClinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.Musculoskeletal safety outcomes of patients receiving daptomycin with HMG-CoA reductase inhibitors.Safety and efficacy of commonly used antimicrobial agents in the treatment of enterococcal infections: a review.Safety and efficacy of high-dose daptomycin as salvage therapy for severe gram-positive bacterial sepsis in hospitalized adult patientsPharmacokinetics of single-dose daptomycin in patients with suspected or confirmed neurological infections.Cutaneous infections and infestations: new therapiesDaptomycin in the Clinical Setting: 8-Year Experience with Gram-positive Bacterial Infections from the EU-CORE(SM) Registry.High-dose daptomycin therapy for staphylococcal endocarditis and when to apply it.Randomized controlled trial of the safety and efficacy of Daptomycin versus standard-of-care therapy for management of patients with osteomyelitis associated with prosthetic devices undergoing two-stage revision arthroplastyEvaluation of Effectiveness and Safety of High-Dose Daptomycin: Results from Patients Included in the European Cubicin(®) Outcomes Registry and Experience.Antimicrobial Stewardship Intervention and Feedback to Infectious Disease Specialists: A Case Study in High-Dose Daptomycin.Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE.Bloodstream infections in the Intensive Care Unit.Efficacy and safety of intravenous daptomycin in Japanese patients with skin and soft tissue infectionsMulticenter study of high-dose daptomycin for treatment of enterococcal infectionsA multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis.High-dose, short-interval daptomycin regimen was safe and well tolerated in three patients with chronic renal failure.Eosinophilic pneumonia associated with daptomycin: a case report and a review of the literature.Treatment of prosthetic osteoarticular infections.Clinical experience with daptomycin for the treatment of patients with knee and hip periprosthetic joint infections.Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults.Current use of daptomycin in cardiac surgery and postoperative intensive care.Vancomycin-resistant enterococcal bacteremia pharmacotherapy.When sepsis persists: a review of MRSA bacteraemia salvage therapy.Possible Hepatotoxicity Associated With Daptomycin: A Case Report and Literature Review.Daptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically Ill Patients.Dosing strategies to optimize currently available anti-MRSA treatment options (Part 1: IV options).Comprehensive Guidance for Antibiotic Dosing in Obese Adults.Daptomycin nonsusceptible vancomycin resistant Enterococcus bloodstream infections in patients with hematological malignancies: risk factors and outcomes.Effect of Daptomycin Dose on the Outcome of Vancomycin-Resistant, Daptomycin-Susceptible Enterococcus faecium Bacteremia.
P2860
Q24620644-2AE3CF5D-DB54-4AF6-8996-5C14EC88798DQ26752922-94B9541F-0A12-4E30-8356-E5712DB542FCQ26853465-139BDF6D-3188-42F1-B0BB-D0D0464950B8Q28488311-E8CD8C80-B582-4F92-B677-C8F1E41C6190Q30795809-D0211D24-DEA9-4CFB-8053-5B9E49AF2263Q33429168-F2814B68-2C9C-41F8-9616-2E9DC1C744E6Q33798246-96441CB5-97CD-4399-B06D-2F861B1C122AQ33844670-AA8697C4-B51B-42B3-92C2-BF08DD8EE2B5Q33845776-725878E9-7B00-45E1-800E-1FEB67C642C8Q33911941-6B53B323-8007-475A-8547-DCEE48B29B58Q34157657-8B79CA3A-351A-4494-92FA-1A277ECDE5E4Q34298999-66E7E3A9-CBA7-42E6-86E1-8F1332EDACBBQ34503844-C6D7431A-885B-40F3-9C6C-6F66FA49F807Q34573702-74BFEA2B-9AA5-4979-B548-24FDD1D02B7CQ35065838-A9BB6773-D02A-47F2-BEC6-92AF8225107DQ35628618-D9257673-B8B3-468A-A3E4-C3D8E9DF4147Q35802607-FCC78D5B-1973-4D78-B916-BFE7E94278E0Q35848781-DED20D1F-BC1D-4F99-AE4A-77CA5B2CEE85Q36364029-90D53936-D19E-4E3C-B0EA-FE4107C97501Q36373724-B4F32F54-A878-4883-A0A6-2FE2E8595E61Q36683458-99D4ADA0-F3DB-48EC-88DD-120F05C6FDC0Q36686882-FB8A2176-EFDC-4FC7-9C11-7DA7361B936FQ36913336-303A7666-1C00-493F-93F8-963C91BDE49EQ36927625-3377819B-D06D-4BE8-9D0F-6EE99BB1B0B5Q37124177-A62CCA94-8025-4952-8D5F-C1146461E4D6Q37286911-50230E64-17BB-40E6-93A6-0D3250C432E3Q37291084-A3D4DC43-20BF-4988-8AC3-4BE38EE82C2DQ37829480-C4814C09-E615-44C3-AA6F-22F2E5237615Q37853179-7EC791CF-B8A2-4AB8-B963-9A3C7EEFAEA7Q38003369-9C2D7DD8-B8E3-4EFD-8677-449EDD388063Q38019839-87CCBE33-9712-4CAE-83B7-78B930A84D70Q38086339-48F31B7D-5F3C-4FF5-90C1-99E7946AEF25Q38263421-FCB1EC87-3A89-4ED2-B340-75436E89352BQ38632488-A84AFB8B-9262-4DAA-A49E-BAAE5D167BAFQ38695556-C056A910-533C-4B70-B489-7034BF6BE77BQ38895642-FC678848-9806-4CC1-819C-6B1361A75BE5Q38907793-32BE09E1-E767-4802-8090-B4B8FDF9C129Q40067964-6935C8FD-4E12-4BD2-ABEE-33C776B2B9BEQ40254524-E79EB740-8E33-49BB-A5FD-342552BC41DEQ40280282-6E8459C9-C31A-43C0-9439-3B1389B27D93
P2860
Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Safety of high-dose intravenou ...... erience in a clinical program.
@en
Safety of high-dose intravenou ...... erience in a clinical program.
@nl
type
label
Safety of high-dose intravenou ...... erience in a clinical program.
@en
Safety of high-dose intravenou ...... erience in a clinical program.
@nl
prefLabel
Safety of high-dose intravenou ...... erience in a clinical program.
@en
Safety of high-dose intravenou ...... erience in a clinical program.
@nl
P2093
P356
P1476
Safety of high-dose intravenou ...... erience in a clinical program.
@en
P2093
A Melchert
B Vardianos
D A Figueroa
M Amodio-Groton
S Segal-Maurer
P304
P356
10.1086/600039
P407
P577
2009-07-01T00:00:00Z